Phase 3 readouts expected in 2029
Every Phase 3 and Phase 2/3 study on a drug AssetMemo covers whose estimated primary completion date falls in 2029, by month. The primary completion date is the sponsor's estimate of when the last participant is assessed for the primary endpoint, so it is the nearest public marker of a readout, not a confirmed date. Dates move: recent moves are on the delayed readouts page, and every phase is on the readout calendar.
Summary
434 studies (374 Phase 3, 60 Phase 2/3) across 331 drugs.
| Indication | Studies |
|---|---|
| Non-Small Cell Lung Cancer | 31 |
| Obesity | 15 |
| Breast Cancer | 13 |
| Multiple Myeloma | 13 |
| Acute Myeloid Leukemia | 11 |
| Heart Failure | 10 |
| HR+/HER2- Metastatic Breast Cancer | 9 |
| Asthma | 8 |
| Chronic Obstructive Pulmonary Disease | 8 |
| Colorectal Cancer | 8 |
| Endometrial Cancer | 7 |
| HIV | 7 |
January 2029
| Primary completion | Drug | Developer | Indication | Phase | Study |
|---|---|---|---|---|---|
| 2029-01 (month only) | Pembrolizumab, pemetrexed | Merck & Co., Eli Lilly | Metastatic Non-squamous Lung Cancer | Phase 3 | NCT05692999 |
| 2029-01 (month only) | Taletrectinib | Eisai, Innovent Biologics, Nippon Kayaku | Non-Small Cell Lung Cancer | Phase 3 | NCT06564324 |
| 2029-01 (month only) | Cetuximab, Tretinoin | Eli Lilly, Merck KGaA, Cheplapharm Arzneimittel GmbH | Oropharynx Cancer, Larynx Cancer, Hypopharynx Cancer, Primary Head and Neck Tumor | Phase 3 | NCT06706401 |
| 2029-01 (month only) | Pumitamig, pemetrexed | BioNTech, Bristol-Myers Squibb, Eli Lilly | Non-Small Cell Lung Cancer | Phase 2/3 | NCT06712316 |
| 2029-01 (month only) | Methylprednisolone | Pfizer | Acute Ischemic Stroke | Phase 3 | NCT06870448 |
| 2029-01 (month only) | Deramciclane, Deraphan | Exciva GmbH | Alzheimer's Disease | Phase 2/3 | NCT07284472 |
| 2029-01 (month only) | dupilumab | Regeneron Pharmaceuticals, Sanofi | Asthma | Phase 3 | NCT07309614 |
| 2029-01 (month only) | Tambotatug pelitecan | MediLink Therapeutics (Suzhou) Co., Ltd., Roche | Pancreatic Ductal Adenocarcinoma | Phase 3 | NCT07803783 |
| 2029-01 (month only) | Suzetrigine | Vertex Pharmaceuticals | Total Knee Arthroplasty (TKA), Total Knee Arthroplasty \(TKA\), Total Knee Replacement, Total Knee Replacement Surgery, Total Knee Replacements, Total Knee Replacement Arthroplasty, Suzetrigine, Pain Management, Pain, Nav 1.8, JOURNAVX, Opioid Cessation, Opioid Consumption, Postoperative, Multimodal Analgesia, Randomized Controlled Trial, Randomized Controlled Study, Randomized Controlled Trials | Phase 3 | NCT07864896 |
| 2029-01 (month only) | Zopapogene imadenovec | Precigen, Inc | Recurrent Respiratory Papillomatosis | Phase 3 | NCT07901738 |
| 2029-01-01 | deucravacitinib | Bristol-Myers Squibb | Psoriasis | Phase 3 | NCT04772079 |
| 2029-01-01 | Nab-paclitaxel, Gemcitabine | Bristol-Myers Squibb, Eli Lilly | Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer | Phase 3 | NCT06897644 |
| 2029-01-01 | Bortezomib, Acalabrutinib | Janssen, Takeda Pharmaceutical Company, AstraZeneca | Hematological Malignancies, Platelet Transfusion Refractoriness (PTR), HLA Antibodies | Phase 3 | NCT07635511 |
| 2029-01-01 | Nab-paclitaxel, Camrelizumab | Bristol-Myers Squibb, Elevar Therapeutics, Inc., Jiangsu Hengrui Pharmaceuticals | Head and Neck Squamous Cell Carcinoma, Locally Advanced Head and Neck Cancer | Phase 3 | NCT07948317 |
| 2029-01-02 | Rilvegostomig | AstraZeneca, COMPUGEN LTD | Biliary Tract Cancer | Phase 3 | NCT06109779 |
| 2029-01-02 | Letrozole, Atirmociclib | Novartis, Pfizer | HR+/HER2- Metastatic Breast Cancer | Phase 3 | NCT06760637 |
| 2029-01-04 | Durvalumab, Tarlatamab | AstraZeneca, Amgen | Small Cell Lung Cancer | Phase 3 | NCT07005128 |
| 2029-01-08 | Sintilimab, Fruquintinib | Innovent Biologics, HUTCHMED, Takeda Pharmaceutical Company | Endometrial Cancer | Phase 3 | NCT06584032 |
| 2029-01-09 | Rimegepant (Nurtec ODT) | Eisai, Pfizer | Migraine | Phase 3 | NCT04649242 |
| 2029-01-11 | zenagamtide | Novo Nordisk | Obesity | Phase 3 | NCT07668401 |
| 2029-01-11 | Daratumumab, Bortezomib, Lenalidomide, Isatuximab, AZD0120, Dexamethasone | Johnson & Johnson, Janssen, Takeda Pharmaceutical Company | Multiple Myeloma | Phase 3 | NCT07764978 |
| 2029-01-12 | Nab-paclitaxel, Pembrolizumab, Sacituzumab Tirumotecan | Bristol-Myers Squibb, Merck & Co., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Non-Small Cell Lung Cancer | Phase 3 | NCT06422143 |
| 2029-01-15 | Dapagliflozin | AstraZeneca, Ono Pharmaceutical | Heart Failure, Chronic Kidney Disease | Phase 3 | NCT07025629 |
| 2029-01-17 | Fazirsiran | Arrowhead Pharmaceuticals, Takeda Pharmaceutical Company | Alpha-1 Antitrypsin Deficiency | Phase 3 | NCT05677971 |
| 2029-01-19 | Pembrolizumab, Rilvegostomig, Trastuzumab Deruxtecan | Merck & Co., AstraZeneca, COMPUGEN LTD | Endometrial Cancer | Phase 3 | NCT06989112 |
| 2029-01-24 | HS-10380 | Hansoh Pharmaceutical Group | Schizophrenia | Phase 3 | NCT07911787 |
| 2029-01-25 | F182112 | Shandong New Time Pharmaceutical Co., Ltd. | Multiple Myeloma | Phase 3 | NCT07579234 |
| 2029-01-26 | Izalontamab brengitecan | Bristol-Myers Squibb, Sichuan Baili Pharmaceutical | Urothelial Carcinoma | Phase 2/3 | NCT07106762 |
| 2029-01-26 | Anifrolumab | AstraZeneca, MedImmune LLC | Systemic Lupus Erythematosus | Phase 3 | NCT07430306 |
| 2029-01-28 | Mosliciguat | Bayer, Pulmovant, Roivant Sciences Ltd. | Pulmonary Hypertension Associated with Interstitial Lung Disease | Phase 3 | NCT07816185 |
| 2029-01-29 | Belumosudil | Kadmon Corporation, Meiji Seika Pharma, Sanofi | Lung Transplant Rejection | Phase 3 | NCT06082037 |
| 2029-01-29 | Balstilimab, Botensilimab, Docetaxel | Agenus Inc., Zydus Lifesciences, Sanofi | Resectable MMR-deficient Solid Tumors, Resectable MMR-proficient Solid Tumors | Phase 2/3 | NCT06279130 |
| 2029-01-29 | Datopotamab Deruxtecan | AstraZeneca, Daiichi Sankyo | Non-Small Cell Lung Cancer | Phase 3 | NCT07291037 |
| 2029-01-31 | Gemcitabine | Eli Lilly | EBV Infection, Stage II Nasopharyngeal Carcinoma AJCC v7, Stage III Nasopharyngeal Carcinoma AJCC v7, Stage IVA Nasopharyngeal Carcinoma AJCC v7, Stage IVB Nasopharyngeal Carcinoma AJCC v7 | Phase 2/3 | NCT02135042 |
| 2029-01-31 | Avelumab | Merck KGaA | Merkel Cell Carcinoma | Phase 3 | NCT03271372 |
| 2029-01-31 | Etelcalcetide | Amgen, Ono Pharmaceutical | Chronic Kidney Disease, Secondary Hyperparathyroidism | Phase 3 | NCT03633708 |
| 2029-01-31 | Methylprednisolone | Pfizer | Cardiac Arrest | Phase 3 | NCT05139849 |
| 2029-01-31 | Carfilzomib, Daratumumab, Pomalidomide, Lenalidomide, Dexamethasone | Amgen, Ono Pharmaceutical, Johnson & Johnson | Multiple Myeloma | Phase 3 | NCT05438043 |
| 2029-01-31 | onabotulinumtoxinA | AbbVie | Migraine | Phase 3 | NCT07040813 |
| 2029-01-31 | Toripalimab, Capecitabine | Coherus BioSciences, Inc., Shanghai Junshi Bioscience, Cheplapharm Arzneimittel GmbH | Gastric Adenocarcinoma | Phase 3 | NCT07584135 |
| 2029-01-31 | tocilizumab | Chugai Pharma, Roche | Acute Ischemic Stroke | Phase 2/3 | NCT07870681 |
| 2029-01-31 | Modafinil | Apotex Inc. | Mitochondrial Disease | Phase 3 | NCT07887412 |
February 2029
| Primary completion | Drug | Developer | Indication | Phase | Study |
|---|---|---|---|---|---|
| 2029-02 (month only) | risankizumab | AbbVie, Boehringer Ingelheim | Crohn's Disease | Phase 3 | NCT03105102 |
| 2029-02 (month only) | Ambroxol | Agyany Pharma Ltd | Parkinson's Disease | Phase 3 | NCT05778617 |
| 2029-02 (month only) | Acalabrutinib | AstraZeneca | Diffuse Large B-Cell Lymphoma | Phase 3 | NCT05820841 |
| 2029-02 (month only) | Pegozafermin | 89bio, Roche | MASH / NASH | Phase 3 | NCT06318169 |
| 2029-02 (month only) | retatrutide | Eli Lilly | Obesity, Chronic Kidney Disease, Atherosclerotic Cardiovascular Disease | Phase 3 | NCT06383390 |
| 2029-02 (month only) | Pembrolizumab, LNS8801 | Merck & Co., Linnaeus Therapeutics, Inc. | Melanoma | Phase 2/3 | NCT06624644 |
| 2029-02 (month only) | Vebreltinib | Apollomics Inc., Avistone Biotechnology | Non-Small Cell Lung Cancer | Phase 3 | NCT06930794 |
| 2029-02 (month only) | upadacitinib | AbbVie | Alopecia Areata | Phase 3 | NCT07023302 |
| 2029-02 (month only) | Remlifanserin | Acadia Pharmaceuticals | Lewy Body Dementia Psychosis | Phase 3 | NCT07095465 |
| 2029-02 (month only) | 131I-apamistamab | Actinium Pharmaceuticals | Acute Myeloid Leukemia | Phase 2/3 | NCT07157514 |
| 2029-02 (month only) | Furmonertinib | Allist Pharmaceuticals, ArriVent BioPharma | Non-Small Cell Lung Cancer | Phase 3 | NCT07185997 |
| 2029-02 (month only) | MLC901 | Moleac Pte Ltd | Alzheimer's Disease | Phase 3 | NCT07191028 |
| 2029-02 (month only) | Ribociclib, Letrozole | Novartis | HR+/HER2- Metastatic Breast Cancer, Breast Cancer | Phase 3 | NCT07340658 |
| 2029-02-01 | Atezolizumab, Bevacizumab | Chugai Pharma, Roche | Hepatocellular Carcinoma | Phase 3 | NCT04712643 |
| 2029-02-01 | Tarlatamab | Amgen | Neuroendocrine Carcinoma | Phase 3 | NCT06937905 |
| 2029-02-01 | Lenalidomide | Bristol-Myers Squibb, Celgene Corporation | Cutaneous Lupus Erythematosus (CLE) | Phase 3 | NCT06965244 |
| 2029-02-01 | Islatravir, Ulonivirine | Merck & Co. | HIV | Phase 2/3 | NCT07266831 |
| 2029-02-01 | Gilteritinib, Venetoclax, Azacitidine | Astellas Pharma, AbbVie, Roche | Acute Myeloid Leukemia | Phase 3 | NCT07407140 |
| 2029-02-04 | Andecaliximab | Ashibio Inc | Fibrodysplasia Ossificans Progressiva | Phase 2/3 | NCT06508021 |
| 2029-02-04 | Vicadrostat | Boehringer Ingelheim | Heart Failure | Phase 3 | NCT06935370 |
| 2029-02-05 | zenagamtide | Novo Nordisk | Obesity | Phase 3 | NCT07822061 |
| 2029-02-06 | Fenfluramine | Nippon Shinyaku, UCB | Rett Syndrome | Phase 3 | NCT07503444 |
| 2029-02-07 | Dexamethasone | Severe Burns | Phase 3 | NCT06968559 | |
| 2029-02-14 | Bortezomib, Lenalidomide, Ciltacabtagene autoleucel, Dexamethasone | Janssen, Takeda Pharmaceutical Company, Bristol-Myers Squibb | Multiple Myeloma | Phase 3 | NCT04923893 |
| 2029-02-14 | Ambrisentan | Gilead Sciences, GlaxoSmithKline | Pulmonary Arterial Hypertension | Phase 3 | NCT07245680 |
| 2029-02-14 | DR10624 | Zhejiang Doer Biologics | Severe Hypertriglyceridemia | Phase 3 | NCT07693777 |
| 2029-02-15 | Felcorekibart | GlaxoSmithKline, Jiangsu Hengrui Pharmaceuticals | Asthma | Phase 3 | NCT07780643 |
| 2029-02-20 | Capecitabine | Cheplapharm Arzneimittel GmbH | Colorectal Cancer | Phase 3 | NCT05797077 |
| 2029-02-21 | Berobenatide | Pfizer | Obesity | Phase 3 | NCT07794774 |
| 2029-02-26 | remibrutinib | Novartis | Chronic Pruritus of Unknown Origin | Phase 3 | NCT07811869 |
| 2029-02-27 | PF-08634404 | Pfizer, Shenyang Sunshine Pharmaceutical | Non-Small Cell Lung Cancer | Phase 3 | NCT07222566 |
| 2029-02-27 | Obinutuzumab | Roche | Lupus Nephritis | Phase 3 | NCT07767188 |
| 2029-02-28 | Palbociclib | Pfizer | HPV-unrelated Head and Neck Squamous Cell Carcinoma | Phase 3 | NCT04966481 |
| 2029-02-28 | Quetiapine (Seroquel) | Cheplapharm Arzneimittel GmbH, Luye Pharma Group | Psychiatric Disorders, Insomnia | Phase 2/3 | NCT06062953 |
| 2029-02-28 | Ribociclib, Camizestrant | Novartis, AstraZeneca | HR+/HER2- Metastatic Breast Cancer, Breast Cancer | Phase 3 | NCT07647328 |
March 2029
| Primary completion | Drug | Developer | Indication | Phase | Study |
|---|---|---|---|---|---|
| 2029-03 (month only) | Venetoclax | AbbVie, Roche | Acute Myeloid Leukemia | Phase 3 | NCT04628026 |
| 2029-03 (month only) | Aficamten | Bayer, Cytokinetics, Sanofi | Hypertrophic Cardiomyopathy | Phase 2/3 | NCT04848506 |
| 2029-03 (month only) | Lepodisiran | Dicerna Pharmaceuticals, Inc., Eli Lilly | Atherosclerotic Cardiovascular Disease | Phase 3 | NCT06292013 |
| 2029-03 (month only) | Plozasiran | Arrowhead Pharmaceuticals, Sanofi | Severe Hypertriglyceridemia, Hypertriglyceridemia | Phase 3 | NCT06880770 |
| 2029-03 (month only) | Cemiplimab | Regeneron Pharmaceuticals | Non-Small Cell Lung Cancer | Phase 3 | NCT06931717 |
| 2029-03 (month only) | Furmonertinib, pemetrexed | Allist Pharmaceuticals, ArriVent BioPharma, Eli Lilly | Non-Small Cell Lung Cancer | Phase 3 | NCT06970639 |
| 2029-03 (month only) | Levosimendan | Orion Corporation, Tenax Therapeutics | Pulmonary Hypertension Associated With HFpEF | Phase 3 | NCT07436689 |
| 2029-03 (month only) | Velinotamig (GR1803) | Cullinan Therapeutics Inc., Genrix Bio, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. | Multiple Myeloma | Phase 3 | NCT07452198 |
| 2029-03 (month only) | Nab-paclitaxel | Bristol-Myers Squibb | Thymoma and Thymic Carcinoma | Phase 2/3 | NCT07463313 |
| 2029-03 (month only) | Mitapivat | AGIOS PHARMACEUTICALS, INC., Avanzanite Bioscience | Non-Transfusion-dependent Alpha-Thalassemia, Non-Transfusion-dependent Beta-Thalassemia | Phase 3 | NCT07517133 |
| 2029-03 (month only) | Lenacapavir (Sunlenca), Teropavimab, Zinlirvimab | Gilead Sciences | HIV | Phase 3 | NCT07682961 |
| 2029-03 (month only) | Lenacapavir (Sunlenca), Teropavimab, Zinlirvimab | Gilead Sciences | HIV | Phase 3 | NCT07683000 |
| 2029-03 (month only) | Sintilimab, Capecitabine | Innovent Biologics, Cheplapharm Arzneimittel GmbH | Anal Squamous Cell Carcinoma, Limited-stage | Phase 3 | NCT07692152 |
| 2029-03 (month only) | Daraxonrasib, Zoldonrasib | BeOne Medicines, Revolution Medicines | Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer | Phase 3 | NCT07805954 |
| 2029-03 (month only) | UBT251 | Novo Nordisk, United Bio-Technology (Hengqin) | Obesity | Phase 3 | NCT07806851 |
| 2029-03 (month only) | Empagliflozin | Boehringer Ingelheim, Eli Lilly | Paraffinoma, Granuloma, Foreign-Body | Phase 2/3 | NCT07828002 |
| 2029-03 (month only) | 7MW3711 | Mabwell Bioscience | Non-Small Cell Lung Cancer | Phase 3 | NCT07831863 |
| 2029-03-03 | Xanomeline/trospium chloride | Bristol-Myers Squibb, Zai Lab | Schizophrenia | Phase 3 | NCT07686263 |
| 2029-03-03 | ALN-CIDEB | Alnylam Pharmaceuticals, Regeneron Pharmaceuticals | MASH / NASH | Phase 3 | NCT07854782 |
| 2029-03-06 | Felcorekibart | GlaxoSmithKline, Jiangsu Hengrui Pharmaceuticals | Nasal Polyps | Phase 3 | NCT07782957 |
| 2029-03-06 | Felcorekibart | GlaxoSmithKline, Jiangsu Hengrui Pharmaceuticals | Nasal Polyps | Phase 3 | NCT07782970 |
| 2029-03-10 | Capecitabine | Cheplapharm Arzneimittel GmbH | Gastric Cancer | Phase 3 | NCT06313567 |
| 2029-03-13 | tezepelumab | Amgen, AstraZeneca | Chronic Obstructive Pulmonary Disease | Phase 3 | NCT06878261 |
| 2029-03-13 | tezepelumab | Amgen, AstraZeneca | Chronic Obstructive Pulmonary Disease | Phase 3 | NCT06883305 |
| 2029-03-14 | Cabotegravir (Apretude) | ViiV Healthcare | HIV | Phase 3 | NCT06134362 |
| 2029-03-14 | Berobenatide | Pfizer | Obesity | Phase 3 | NCT07794761 |
| 2029-03-15 | Iberdomide | Bristol-Myers Squibb | Multiple Myeloma | Phase 3 | NCT05827016 |
| 2029-03-15 | metformin | Idiopathic Pulmonary Fibrosis | Phase 3 | NCT07520110 | |
| 2029-03-15 | Vatiquinone (PTC743) | PTC Therapeutics | Friedreich Ataxia | Phase 3 | NCT07681713 |
| 2029-03-17 | JSKN016 | Alphamab Oncology | Triple Negative Breast Cancer | Phase 3 | NCT07533123 |
| 2029-03-19 | Dostarlimab | GlaxoSmithKline | Colonic Neoplasms, Neoplasms, Colon | Phase 3 | NCT05855200 |
| 2029-03-19 | metformin | Pre-Eclampsia Onset Less Than 37 Weeks, Pre-Eclampsia, Pre-Eclampsia | Phase 3 | NCT06452498 | |
| 2029-03-27 | Rimegepant (Nurtec ODT) | Eisai, Pfizer | Migraine | Phase 3 | NCT05156398 |
| 2029-03-27 | Methylprednisolone | Pfizer | Hepatectomy | Phase 3 | NCT07507643 |
| 2029-03-28 | Cetuximab, Calderasib | Eli Lilly, Merck KGaA, Merck & Co. | Colon Adenocarcinoma, Rectal Adenocarcinoma | Phase 3 | NCT06997497 |
| 2029-03-28 | Cenvacibart, Amrecibart | Regeneron Pharmaceuticals | Atrial Fibrillation (AF) | Phase 3 | NCT07430956 |
| 2029-03-30 | remibrutinib | Novartis | IgE-Mediated Food Allergy, Peanut Allergy, Cow Milk Allergy, Egg Allergy | Phase 3 | NCT07768371 |
| 2029-03-31 | Pembrolizumab | Merck & Co. | Head and Neck Squamous Cell Carcinoma | Phase 3 | NCT05721755 |
| 2029-03-31 | Fulvestrant, Palbociclib, Letrozole, Gedatolisib | AstraZeneca, Pfizer, Novartis | HR+/HER2- Metastatic Breast Cancer, Breast Cancer | Phase 3 | NCT06757634 |
| 2029-03-31 | Semaglutide (Ozempic) | Novo Nordisk | Alcohol Use Disorder | Phase 3 | NCT07218354 |
| 2029-03-31 | Pembrolizumab, Nivolumab, Brentuximab Vedotin | Merck & Co., Bristol-Myers Squibb, Ono Pharmaceutical | Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma | Phase 2/3 | NCT07572123 |
April 2029
May 2029
| Primary completion | Drug | Developer | Indication | Phase | Study |
|---|---|---|---|---|---|
| 2029-05 (month only) | N-acetylcysteine | Apotex Inc., Phebra Pty Ltd | Retinitis Pigmentosa | Phase 3 | NCT05537220 |
| 2029-05 (month only) | zanubrutinib | BeOne Medicines | Splenic Marginal Zone Lymphoma | Phase 3 | NCT05735834 |
| 2029-05 (month only) | Olomorasib | Eli Lilly | Non-Small Cell Lung Cancer | Phase 3 | NCT06890598 |
| 2029-05 (month only) | Osavampator | Neurocrine Biosciences, Takeda Pharmaceutical Company | Major Depressive Disorder | Phase 3 | NCT06966401 |
| 2029-05 (month only) | Tersolisib | Eli Lilly | HR+/HER2- Metastatic Breast Cancer, Breast Cancer | Phase 3 | NCT07174336 |
| 2029-05 (month only) | Bevacizumab, Telisotuzumab Adizutecan | Roche, AbbVie | Colorectal Cancer, Metastatic Colorectal Cancer, Advanced Metastatic Colorectal Cancer | Phase 3 | NCT07525206 |
| 2029-05 (month only) | Delpacibart zotadirsen | Novartis | Muscular Dystrophies, Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy), Muscular Disorders, Atrophic, Muscular Disease, Musculoskeletal Diseases, Neuromuscular Diseases (NMD), Nervous System Diseases, Genetic Diseases, X-Linked, Hereditary, Neonatal Disease, Duchene Muscular Dystrophy, Congenital, DMD | Phase 3 | NCT07587242 |
| 2029-05 (month only) | Toripalimab | Coherus BioSciences, Inc., Shanghai Junshi Bioscience | Non-Small Cell Lung Cancer | Phase 3 | NCT07608159 |
| 2029-05 (month only) | safusidenib | Nuvation Bio | Glioma | Phase 3 | NCT07712757 |
| 2029-05-01 | Tislelizumab | BeOne Medicines | Laryngeal Carcinoma, Hypopharyngeal Carcinoma | Phase 3 | NCT06957938 |
| 2029-05-01 | metformin | COPD | Phase 3 | NCT06999343 | |
| 2029-05-01 | Capecitabine, Bizrolertinib | Cheplapharm Arzneimittel GmbH, Roche | HER2-Positive Breast Cancer | Phase 2/3 | NCT07413939 |
| 2029-05-01 | Disitamab Vedotin | Pfizer, RemeGen Co., Ltd. | Urothelial Carcinoma | Phase 3 | NCT07498907 |
| 2029-05-03 | Navlimetostat | Bristol-Myers Squibb | Pancreatic Ductal Adenocarcinoma | Phase 2/3 | NCT07076121 |
| 2029-05-04 | Felcorekibart | GlaxoSmithKline, Jiangsu Hengrui Pharmaceuticals | Asthma | Phase 3 | NCT07782996 |
| 2029-05-10 | Daraxonrasib | BeOne Medicines, Revolution Medicines | Pancreatic Ductal Adenocarcinoma | Phase 3 | NCT07252232 |
| 2029-05-11 | Pembrolizumab, Datopotamab Deruxtecan | Merck & Co., AstraZeneca, Daiichi Sankyo | Non-Small Cell Lung Cancer | Phase 3 | NCT05555732 |
| 2029-05-14 | duvakitug | Sanofi, Teva Pharmaceutical Industries | Crohn's Disease | Phase 3 | NCT07184931 |
| 2029-05-14 | Nerandomilast (Jascayd) | Boehringer Ingelheim | Familial Pulmonary Fibrosis, Interstitial Lung Abnormalities, Interstitial Lung Diseases | Phase 3 | NCT07201922 |
| 2029-05-21 | Carfilzomib, Daratumumab, Pomalidomide, Bortezomib, Linvoseltamab, Dexamethasone | Amgen, Ono Pharmaceutical, Johnson & Johnson | Multiple Myeloma | Phase 3 | NCT07222761 |
| 2029-05-26 | Ulotaront | Otsuka Holdings | Generalized Anxiety Disorder | Phase 3 | NCT07786454 |
| 2029-05-29 | Doravirine/islatravir (Idvynso) | Merck & Co. | HIV | Phase 3 | NCT04776252 |
| 2029-05-30 | tofacitinib, Abatacept, tocilizumab | Pfizer, Bristol-Myers Squibb, Chugai Pharma | Polyarticular Course Juvenile Idiopathic Arthritis (JIA) | Phase 3 | NCT06654882 |
| 2029-05-31 | Elafibranor | Genfit, Ipsen | Primary Biliary Cholangitis | Phase 3 | NCT06016842 |
| 2029-05-31 | Fulvestrant, Dalpiciclib, JS105 | AstraZeneca, Jiangsu Hengrui Pharmaceuticals, Risen (Suzhou) Pharma Tech Co., Ltd. | HR+/HER2- Metastatic Breast Cancer, Breast Cancer | Phase 3 | NCT07207070 |
| 2029-05-31 | Telitacicept | RemeGen Co., Ltd., Vor Bio | CTD-ILD | Phase 3 | NCT07495033 |
| 2029-05-31 | IBI3003 | Innovent Biologics | Multiple Myeloma | Phase 3 | NCT07623798 |
| 2029-05-31 | Methotrexate | Rheumatoid Arthritis | Phase 2/3 | NCT07627893 | |
| 2029-05-31 | Freneslerbart/mevonlerbart | Regeneron Pharmaceuticals | Allergic Conjunctivitis, Cat Allergy | Phase 3 | NCT07675811 |
June 2029
| Primary completion | Drug | Developer | Indication | Phase | Study |
|---|---|---|---|---|---|
| 2029-06 (month only) | upadacitinib | AbbVie | Juvenile Idiopathic Arthritis | Phase 3 | NCT05609630 |
| 2029-06 (month only) | Iparomlimab and tuvonralimab | Qilu Pharmaceutical | Non-Small Cell Lung Cancer | Phase 3 | NCT05690945 |
| 2029-06 (month only) | Docetaxel | Sanofi | Hormone Receptor Positive HER-2 Negative Breast Cancer | Phase 3 | NCT05901428 |
| 2029-06 (month only) | Sacituzumab Govitecan | Gilead Sciences | Endometrial Cancer | Phase 3 | NCT06486441 |
| 2029-06 (month only) | Lisaftoclax | Ascentage Pharma Group Inc. | Higher-risk Myelodysplastic Syndrome | Phase 3 | NCT06641414 |
| 2029-06 (month only) | Revumenib | Syndax | Acute Myeloid Leukemia | Phase 3 | NCT07211958 |
| 2029-06 (month only) | Azetukalner | Xenon Pharmaceuticals | Bipolar Depression, Bipolar I Disorder, Bipolar Disorder, Bipolar II Disorder | Phase 3 | NCT07217860 |
| 2029-06 (month only) | Donidalorsen | Ionis Pharmaceuticals, Otsuka Holdings, Theratechnologies | Hereditary Angioedema | Phase 3 | NCT07298447 |
| 2029-06 (month only) | Imatinib mesylate prodrug (IkT-001Pro) | Inhibikase Therapeutics | Pulmonary Arterial Hypertension | Phase 3 | NCT07365332 |
| 2029-06 (month only) | BMN 333 | BioMarin Pharmaceutical | Achondroplasia | Phase 2/3 | NCT07441876 |
| 2029-06 (month only) | Mitapivat | AGIOS PHARMACEUTICALS, INC., Avanzanite Bioscience | Transfusion-Dependent Beta Thalassemia | Phase 3 | NCT07506863 |
| 2029-06 (month only) | TSC-101 | TScan Therapeutics, Inc. | Hematologic Malignancies | Phase 3 | NCT07702578 |
| 2029-06 (month only) | Serplulimab, Tambotatug pelitecan | Abbott, Accord Healthcare, Eisai | Small Cell Lung Cancer | Phase 3 | NCT07739758 |
| 2029-06 (month only) | Darunavir, Dolutegravir, tenofovir alafenamide (Vemlidy), Emtricitabine (Emtriva) | Johnson & Johnson, Shionogi, ViiV Healthcare | HIV | Phase 3 | NCT07792096 |
| 2029-06 (month only) | JADE101 | Jade Biosciences, Inc. | IgA Nephropathy | Phase 3 | NCT07902817 |
| 2029-06-01 | Datopotamab Deruxtecan | AstraZeneca, Daiichi Sankyo | Urothelial Carcinoma | Phase 2/3 | NCT07129993 |
| 2029-06-01 | Plinabulin | BeyondSpring Pharmaceuticals, Jiangsu Hengrui Pharmaceuticals | Non-Small Cell Lung Cancer | Phase 3 | NCT07361484 |
| 2029-06-01 | Atezolizumab | Chugai Pharma, Roche | Hepatocellular Carcinoma | Phase 3 | NCT07461675 |
| 2029-06-01 | Sutantatug envedotin | Corbus Pharmaceuticals, CSPC Megalith Biopharmaceutical | Urothelial Carcinoma | Phase 3 | NCT07526792 |
| 2029-06-01 | PF-08634404 | Pfizer, Shenyang Sunshine Pharmaceutical | Endometrial Cancer | Phase 3 | NCT07578649 |
| 2029-06-01 | tilrekimig | Pfizer | Asthma | Phase 3 | NCT07772921 |
| 2029-06-04 | Sarilumab | Regeneron Pharmaceuticals, Sanofi | Polymyalgia Rheumatica | Phase 3 | NCT07286214 |
| 2029-06-04 | Zadavotide guraxetan | AstraZeneca | Metastatic Castration-Resistant Prostate Cancer | Phase 3 | NCT07611110 |
| 2029-06-05 | survodutide | Boehringer Ingelheim, Zealand Pharma | MASH / NASH | Phase 3 | NCT06632457 |
| 2029-06-07 | tilrekimig | Pfizer | Asthma | Phase 3 | NCT07869043 |
| 2029-06-15 | INCA033989 | Incyte | Essential Thrombocythemia | Phase 3 | NCT07623200 |
| 2029-06-18 | Pembrolizumab, Amivantamab | Merck & Co., Genmab, Johnson & Johnson | Head and Neck Squamous Cell Carcinoma | Phase 3 | NCT07276399 |
| 2029-06-19 | etrasimod | Everest Medicines (Beijing) Co., Ltd., Pfizer | Ulcerative Colitis | Phase 3 | NCT03950232 |
| 2029-06-22 | bleximenib | Johnson & Johnson | Acute Myeloid Leukemia | Phase 3 | NCT06852222 |
| 2029-06-22 | Xanomeline/trospium chloride | Bristol-Myers Squibb, Zai Lab | Alzheimer's Disease | Phase 3 | NCT06937229 |
| 2029-06-25 | Cenvacibart, Amrecibart | Regeneron Pharmaceuticals | Venous Thromboembolism | Phase 3 | NCT07697599 |
| 2029-06-26 | Litifilimab | Biogen | Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus | Phase 3 | NCT06044337 |
| 2029-06-26 | zenagamtide | Novo Nordisk | Obesity | Phase 3 | NCT07339423 |
| 2029-06-27 | Povetacicept | Vertex Pharmaceuticals | Primary Membranous Nephropathy | Phase 2/3 | NCT07204275 |
| 2029-06-29 | Coramitug | Novo Nordisk | Heart Failure | Phase 3 | NCT07207811 |
| 2029-06-30 | Bevacizumab | Roche | Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8 | Phase 3 | NCT04181060 |
| 2029-06-30 | Gilteritinib, Gemtuzumab Ozogamicin, Vyxeos, Methotrexate | Astellas Pharma, Pfizer, Handok | Acute Myeloid Leukemia | Phase 3 | NCT04293562 |
| 2029-06-30 | Cetuximab | Eli Lilly, Merck KGaA | Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Stage IV Colorectal Cancer AJCC v8, Unresectable Colorectal Carcinoma | Phase 3 | NCT05863195 |
| 2029-06-30 | Semaglutide (Wegovy) | Novo Nordisk | Kidney Transplant Recipient | Phase 2/3 | NCT06913023 |
| 2029-06-30 | Zanzalintinib | Exelixis | Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET) | Phase 2/3 | NCT06943755 |
| 2029-06-30 | Durvalumab | AstraZeneca | Small Cell Lung Cancer | Phase 3 | NCT06992609 |
| 2029-06-30 | Purinostat Mesylate | Chengdu Zenitar Biomedical Technology | Diffuse Large B-Cell Lymphoma | Phase 3 | NCT07011056 |
| 2029-06-30 | Prasinezumab | Prothena Biosciences Limited, Roche | Parkinson's Disease | Phase 3 | NCT07174310 |
| 2029-06-30 | Tislelizumab, Disitamab Vedotin | BeOne Medicines, Pfizer, RemeGen Co., Ltd. | Gastric Carcinoma | Phase 3 | NCT07315750 |
| 2029-06-30 | Everolimus | Novartis | Liver Allograft, Liver Diseases, Liver Transplantation | Phase 3 | NCT07739914 |
July 2029
August 2029
| Primary completion | Drug | Developer | Indication | Phase | Study |
|---|---|---|---|---|---|
| 2029-08 (month only) | Carfilzomib, Lenalidomide, Elotuzumab, Dexamethasone | Amgen, Ono Pharmaceutical, Bristol-Myers Squibb | Multiple Myeloma | Phase 3 | NCT03948035 |
| 2029-08 (month only) | Eplontersen | AstraZeneca, Ionis Pharmaceuticals | Hereditary Transthyretin-Mediated Amyloid Polyneuropathy | Phase 3 | NCT05071300 |
| 2029-08 (month only) | Eplontersen | AstraZeneca, Ionis Pharmaceuticals | Transthyretin Amyloidosis with Cardiomyopathy | Phase 3 | NCT05667493 |
| 2029-08 (month only) | Tamoxifen (Soltamox), Anastrozole, Letrozole, Elacestrant, Exemestane | Mayne Pharma, Rosemont Pharmaceuticals, ANI Pharmaceuticals, Inc. | Breast Cancer | Phase 3 | NCT06492616 |
| 2029-08 (month only) | Annamycin | Moleculin | Acute Myeloid Leukemia | Phase 2/3 | NCT06788756 |
| 2029-08 (month only) | Rinatabart sesutecan (Rina-S) | Genmab | Endometrial Cancer | Phase 3 | NCT07166094 |
| 2029-08 (month only) | Dapagliflozin | AstraZeneca, Ono Pharmaceutical | Septic Shock | Phase 3 | NCT07488689 |
| 2029-08 (month only) | Mitapivat | AGIOS PHARMACEUTICALS, INC., Avanzanite Bioscience | Sickle Cell Disease | Phase 3 | NCT07656415 |
| 2029-08 (month only) | orforglipron | Chugai Pharma, Eli Lilly | Obesity, Hypertension | Phase 3 | NCT07794579 |
| 2029-08-01 | Niraparib | GlaxoSmithKline, Zai Lab | Ovarian Cancer | Phase 3 | NCT05659381 |
| 2029-08-01 | mazdutide | Eli Lilly, Innovent Biologics | Type 2 Diabetes | Phase 3 | NCT07083154 |
| 2029-08-04 | Fitusiran | Alnylam Pharmaceuticals, Sanofi | Hemophilia | Phase 3 | NCT07285460 |
| 2029-08-05 | zasocitinib | Takeda Pharmaceutical Company | Psoriasis | Phase 3 | NCT06550076 |
| 2029-08-06 | Xanomeline/trospium chloride | Bristol-Myers Squibb, Zai Lab | Irritability Associated With Autism Spectrum Disorder | Phase 3 | NCT07284745 |
| 2029-08-06 | Xanomeline/trospium chloride | Bristol-Myers Squibb, Zai Lab | Irritability Associated With Autism Spectrum Disorder | Phase 3 | NCT07285798 |
| 2029-08-13 | duvakitug | Sanofi, Teva Pharmaceutical Industries | Crohn's Disease | Phase 3 | NCT07184944 |
| 2029-08-13 | Cabotegravir/rilpivirine (Cabenuva) | ViiV Healthcare | HIV | Phase 3 | NCT07650916 |
| 2029-08-15 | Gabapentin | Pfizer, Viatris | Head and Neck Squamous Cell Carcinoma, Stage I Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage II Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8 | Phase 3 | NCT06992427 |
| 2029-08-15 | Methylprednisolone, Frexalimab | Pfizer, Sanofi | Kidney Transplant Rejection | Phase 2/3 | NCT07412470 |
| 2029-08-15 | VAY736 | Novartis | Sjögren's Disease | Phase 3 | NCT07621809 |
| 2029-08-16 | Nivolumab, Rilvegostomig, Capecitabine, Sonesitatug vedotin | Bristol-Myers Squibb, Ono Pharmaceutical, AstraZeneca | Gastric Cancer | Phase 3 | NCT07431281 |
| 2029-08-18 | tezepelumab | Amgen, AstraZeneca | Asthma | Phase 3 | NCT07013123 |
| 2029-08-18 | Cenvacibart, Amrecibart | Regeneron Pharmaceuticals | Peripheral Artery Disease (PAD) | Phase 3 | NCT07318610 |
| 2029-08-18 | Cadonilimab | Akeso | Gastric / Gastroesophageal Junction Adenocarcinoma | Phase 3 | NCT07700979 |
| 2029-08-20 | Vericiguat | Bayer, Merck & Co. | Heart Failure | Phase 2/3 | NCT05714085 |
| 2029-08-30 | Lurbinectedin | Jazz Pharmaceuticals, Luye Pharma Group, Merck KGaA | Leiomyosarcoma | Phase 3 | NCT06088290 |
| 2029-08-31 | Setidegrasib | Astellas Pharma | Pancreatic Ductal Adenocarcinoma | Phase 3 | NCT07409272 |
| 2029-08-31 | Capecitabine | Cheplapharm Arzneimittel GmbH | Newly Diagnosed Triple-negative Breast Cancer | Phase 3 | NCT07869628 |
September 2029
October 2029
| Primary completion | Drug | Developer | Indication | Phase | Study |
|---|---|---|---|---|---|
| 2029-10 (month only) | Atezolizumab, Capmatinib, Trametinib, Alectinib, Cobimetinib, Entrectinib, Dabrafenib, Pertuzumab, Vemurafenib | Chugai Pharma, Roche, Incyte | Haematological Malignancy, Solid Tumour | Phase 2/3 | NCT05722886 |
| 2029-10 (month only) | Cobimetinib, Vemurafenib | Exelixis, Roche | Melanoma | Phase 2/3 | NCT05768178 |
| 2029-10 (month only) | Alectinib | Chugai Pharma, Roche | Haematological Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Cancer, Anaplastic Large Cell Lymphoma, Lymphoma, Renal Cell Carcinoma, Neuroblastoma, Solid Tumour | Phase 2/3 | NCT05770037 |
| 2029-10 (month only) | Atezolizumab | Chugai Pharma, Roche | Colorectal Cancer, Melanoma | Phase 2/3 | NCT05770102 |
| 2029-10 (month only) | Entrectinib | Chugai Pharma, Roche | Haematological Malignancy, Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Cancer, Brain Neoplasms, Melanoma, Glioma, Solid Tumour | Phase 2/3 | NCT05770544 |
| 2029-10 (month only) | Pertuzumab | Roche | Haematological Malignancy, Colorectal Neoplasms, Urinary Bladder Neoplasm, Gallbladder Neoplasms, Salivary Gland Neoplasm, Lung Neoplasm, Pancreatic Neoplasm, Ovarian Neoplasms, Prostatic Neoplasm, Skin Neoplasm, Solid Tumour | Phase 2/3 | NCT05786716 |
| 2029-10 (month only) | Durvalumab | AstraZeneca | Non-Small Cell Lung Cancer | Phase 3 | NCT06284317 |
| 2029-10 (month only) | Sacituzumab Govitecan, Lurbinectedin | Gilead Sciences, Jazz Pharmaceuticals, Luye Pharma Group | Small Cell Lung Cancer | Phase 3 | NCT06801834 |
| 2029-10 (month only) | Capmatinib | Incyte, Novartis | Solid Tumour, Haematological Malignancy, Malignant Neoplasm, Neoplasms by Histologic Type, Neoplasms by Site, Cancer, Malignancy, Glioma, Neuroblastoma, Gastric Cancer, Soft Tissue Sarcoma | Phase 2/3 | NCT06988475 |
| 2029-10 (month only) | Camrelizumab, Apatinib | Elevar Therapeutics, Inc., Jiangsu Hengrui Pharmaceuticals, Advenchen Laboratories | Hepato Cellular Carcinoma (HCC), Chemotherapy Effect | Phase 3 | NCT07267806 |
| 2029-10 (month only) | Trametinib, Dabrafenib | Novartis | Glioma | Phase 2/3 | NCT07440290 |
| 2029-10 (month only) | Pirtobrutinib, bexobrutideg | Eli Lilly, Nurix Therapeutics, Inc., Roche | Chronic Lymphocytic Leukemia, Relapsed/Refractory Chronic Lymphocytic Leukemia | Phase 3 | NCT07516093 |
| 2029-10 (month only) | Zoldonrasib | Revolution Medicines | Non-Small Cell Lung Cancer | Phase 3 | NCT07777822 |
| 2029-10 (month only) | eloralintide, Tirzepatide (Zepbound) | Eli Lilly | Obesity | Phase 3 | NCT07881432 |
| 2029-10 (month only) | eloralintide, Tirzepatide (Zepbound) | Eli Lilly | Obesity | Phase 3 | NCT07881458 |
| 2029-10-01 | Pembrolizumab | Merck & Co. | Gastric Cancer | Phase 3 | NCT06093425 |
| 2029-10-01 | Zipalertinib | Cullinan Therapeutics Inc., Taiho Pharmaceutical | Non-Small Cell Lung Cancer | Phase 3 | NCT07128199 |
| 2029-10-01 | Toripalimab | Coherus BioSciences, Inc., Shanghai Junshi Bioscience | Esophageal Cancer | Phase 3 | NCT07332221 |
| 2029-10-01 | Sintilimab, Ipilimumab | Innovent Biologics, Bristol-Myers Squibb, Ono Pharmaceutical | Locally Advanced Rectal Cancer (LARC) | Phase 2/3 | NCT07879586 |
| 2029-10-01 | Sintilimab, Ipilimumab | Innovent Biologics, Bristol-Myers Squibb, Ono Pharmaceutical | Locally Advanced Rectal Cancer (LARC) | Phase 2/3 | NCT07879599 |
| 2029-10-01 | CPO301, Enlonstobart | Conjupro Biotherapeutics, Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Hangzhou Sumgen Biotech Co., Ltd. | Previously Systemic Treatment-Naive Recurrent or Metastatic Nasopharyngeal Carcinoma | Phase 3 | NCT07925021 |
| 2029-10-03 | Riliprubart | Sanofi | Polyneuropathy, Inflammatory Demyelinating, Chronic | Phase 3 | NCT06859099 |
| 2029-10-12 | deucravacitinib | Bristol-Myers Squibb | Psoriasis | Phase 3 | NCT06979453 |
| 2029-10-16 | Bevacizumab, precemtabart tocentecan | Roche, Merck KGaA | Colorectal Cancer, Metastatic Colorectal Cancer | Phase 3 | NCT07549412 |
| 2029-10-26 | Intismeran Autogene | Merck & Co., Moderna | Melanoma | Phase 3 | NCT05933577 |
| 2029-10-26 | Laroprovstat | AstraZeneca | Atherosclerotic Cardiovascular Disease | Phase 3 | NCT07000357 |
| 2029-10-30 | JS207 | Shanghai Junshi Bioscience | Hepatocellular Carcinoma | Phase 3 | NCT07823348 |
| 2029-10-31 | Temozolomide | Merck & Co. | Glioma | Phase 3 | NCT00887146 |
November 2029
| Primary completion | Drug | Developer | Indication | Phase | Study |
|---|---|---|---|---|---|
| 2029-11 (month only) | alprostadil | Biopeutics, Pfizer | Heart Failure | Phase 3 | NCT00610051 |
| 2029-11 (month only) | Bevacizumab, Regorafenib | Roche, Bayer | Colorectal Cancer, Metastatic Colorectal Cancer, Advanced Metastatic Colorectal Cancer | Phase 2/3 | NCT05462613 |
| 2029-11 (month only) | upadacitinib | AbbVie | Atopic Dermatitis | Phase 3 | NCT06461897 |
| 2029-11 (month only) | Inobrodib, Pomalidomide, Dexamethasone | CellCentric Ltd., Bristol-Myers Squibb | Multiple Myeloma | Phase 3 | NCT07772024 |
| 2029-11 (month only) | eloralintide | Eli Lilly | Obesity | Phase 3 | NCT07900633 |
| 2029-11-01 | Gemcitabine, Docetaxel | Eli Lilly, Sanofi | Non-muscle-invasive Bladder Cancer | Phase 3 | NCT05538663 |
| 2029-11-01 | Durvalumab | AstraZeneca | Gastric, Esophagogastric Junction | Phase 3 | NCT07877818 |
| 2029-11-06 | survodutide | Boehringer Ingelheim, Zealand Pharma | Obesity | Phase 3 | NCT07855900 |
| 2029-11-15 | Tislelizumab, Brentuximab Vedotin | BeOne Medicines, Pfizer, Seagen | Classical Hodgkin Lymphoma, Child, Adolescent, Young Adult, Metabolic Response, Survival, Treatment, Brentuximab Vedotin, PET Scan | Phase 2/3 | NCT06563245 |
| 2029-11-16 | Brivaracetam | UCB | Epilepsy | Phase 3 | NCT06315322 |
| 2029-11-27 | lunsekimig | Sanofi | Chronic Obstructive Pulmonary Disease | Phase 3 | NCT07190209 |
| 2029-11-27 | lunsekimig | Sanofi | Chronic Obstructive Pulmonary Disease | Phase 3 | NCT07190222 |
| 2029-11-29 | Enlicitide | Merck & Co. | Atherosclerotic Cardiovascular Disease | Phase 3 | NCT06008756 |
| 2029-11-30 | Finerenone | Bayer | Heart Failure | Phase 3 | NCT07188805 |
| 2029-11-30 | Fenebrutinib | Roche | Multiple Sclerosis | Phase 3 | NCT07937852 |
December 2029
Source: ClinicalTrials.gov, each study's record, checked daily. Studies that are terminated, withdrawn or completed are left out, as are programmes their developer has stopped. A month-only date is shown as given.